Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13059576 | 0.91 | CTSB (0.41) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL11983928 | 0.91 | CTSB (0.41) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL6384336 | 0.91 | CTSB (0.41) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL8202772 | 0.91 | CTSB (0.41) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL11976235 | 0.91 | CTSB (0.42) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL13924635 | 0.90 | CTSB (0.41) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL13082706 | 0.90 | CTSB (0.39) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL11976262 | 0.90 | CTSB (0.39) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL11976261 | 0.90 | CTSB (0.39) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL3432919 | 0.90 | CTSB (0.41) | CTSBCTSSCYP3A4ADRB3ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003604-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003604-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003604-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| US-20080159982-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-03 | — | — | US | disclosed |
| US-20080159982-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-03 | — | — | US | disclosed |
| WO-2008064057-A1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080159982-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, VIP | CTSB 268/4885CTSS 703/4885CYP3A4 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.